KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Cash from Financing Activities (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Cash from Financing Activities for 13 consecutive years, with $113.5 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 836.0% to $113.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $117.1 million through Dec 2025, up 865.48% year-over-year, with the annual reading at $117.1 million for FY2025, 865.48% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $113.5 million at Xenon Pharmaceuticals, up from $2.4 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $324.0 million in Q4 2023, with the low at $6000.0 in Q4 2022.
  • Average Cash from Financing Activities over 5 years is $84.2 million, with a median of $6.3 million recorded in 2021.
  • The sharpest move saw Cash from Financing Activities crashed 100.0% in 2022, then surged 5400133.33% in 2023.
  • Over 5 years, Cash from Financing Activities stood at $324.0 million in 2021, then plummeted by 100.0% to $6000.0 in 2022, then soared by 5400133.33% to $324.0 million in 2023, then plummeted by 96.26% to $12.1 million in 2024, then skyrocketed by 836.0% to $113.5 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $113.5 million, $2.4 million, and $65000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.